Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.
about
Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort studyPaucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndromeRole of interleukin-4 in resistance to Cryptococcus neoformans infectionCryptococcal interactions with the host immune system.Improved survival of mice deficient in secretory immunoglobulin M following systemic infection with Cryptococcus neoformansOpsonic requirements for dendritic cell-mediated responses to Cryptococcus neoformans.IgM(+) memory B cell expression predicts HIV-associated cryptococcosis status.Antibody-mediated protection against Cryptococcus neoformans pulmonary infection is dependent on B cellsCryptococcus neoformans hyperfilamentous strain is hypervirulent in a murine model of cryptococcal meningoencephalitis.TLR9 signaling is required for generation of the adaptive immune protection in Cryptococcus neoformans-infected lungs.Cryptococcus neoformans-reactive and total immunoglobulin profiles of human immunodeficiency virus-infected and uninfected UgandansImmunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3Cytokine signaling regulates the outcome of intracellular macrophage parasitism by Cryptococcus neoformans.A nonproliferating parvovirus vaccine vector elicits sustained, protective humoral immunity following a single intravenous or intranasal inoculationHuman immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.Galactoxylomannan does not exhibit cross-reactivity in the platelia Aspergillus enzyme immunoassay.New concepts in antibody-mediated immunity.Biosynthesis and immunogenicity of glucosylceramide in Cryptococcus neoformans and other human pathogens.Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models.Increased activity of the complement system in cerebrospinal fluid of the patients with Non-HIV Cryptococcal meningitis.Cryptococcal genotype influences immunologic response and human clinical outcome after meningitis.Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infectionProtective and destructive immunity in the periodontium: Part 1--innate and humoral immunity and the periodontium.Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannanPhenotypic switching in Cryptococcus neoformans contributes to virulence by changing the immunological host responseThe capsule of the fungal pathogen Cryptococcus neoformans.The intracellular life of Cryptococcus neoformans.Catch me if you can: phagocytosis and killing avoidance by Cryptococcus neoformans.Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases.Cryptococcus antigens and immune responses: implications for a vaccine.The protective role of immunoglobulins in fungal infections and inflammation.Role of capsule and interleukin-6 in long-term immune control of Cryptococcus neoformans infection by specifically activated human peripheral blood mononuclear cells.Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with pleotrophic effects on cytokine and leukocyte responses.The monoclonal antibody against the major diagnostic antigen of Paracoccidioides brasiliensis mediates immune protection in infected BALB/c mice challenged intratracheally with the fungus.The formation of titan cells in Cryptococcus neoformans depends on the mouse strain and correlates with induction of Th2-type responses.Lack of IL-6 increases blood-brain barrier permeability in fungal meningitis.Early or late IL-10 blockade enhances Th1 and Th17 effector responses and promotes fungal clearance in mice with cryptococcal lung infectionRoles of CD4+ T-cell-independent and -dependent antibody responses in the control of influenza virus infection: evidence for noncognate CD4+ T-cell activities that enhance the therapeutic activity of antiviral antibodies.Experimental systemic infection with Cryptococcus neoformans var. grubii and Cryptococcus gattii in normal and immunodeficient mice.Adaptive Immunity to Cryptococcus neoformans Infections.
P2860
Q21144623-CB654A7C-DFB4-410D-8B39-6210018CBFC1Q24630287-609938E9-01A6-4533-A747-56C227B09A43Q28513197-F72CCAF1-F9A4-4936-91F7-78507E788C4BQ30387948-EBA83378-A21D-483E-8A45-CB230C17012BQ33557968-9308A8CE-6A7F-4C12-8032-C1F5582D3BA1Q33559279-A326E8D6-691D-496B-AE47-547F0999754CQ33585837-3E3B8290-BF27-4F3F-AB53-F0EBBD427785Q33793546-C479BF51-DF3B-4235-917A-8FCBBD6A17BEQ34005219-274C4C3E-91F2-4519-8AE3-E643E517E240Q34033551-CE92983A-EC1E-4B07-BA0F-103516C2690BQ34072411-D97FB996-D3FC-4FD3-A250-ED1CFFB5E63DQ34121516-318C780A-5E2A-4433-9191-9CBF7A4A6A3BQ34984326-D5C8A35E-7BD7-49DD-BA67-06A5BDF76728Q35543174-0D8B8B8B-9A9F-4473-BC9E-D2EE87DCF744Q35689463-1C3CB2C2-ECF5-482A-B9D3-3214AE1C2DBEQ35783564-B0C8E6E9-0C1C-4E9D-AF6F-9960CF3E1C1DQ35926507-198606E9-75C4-4917-BCBB-348D5C2650A1Q36095320-2A643CF8-F5A4-4307-A2DE-CFEB297EC97FQ36192774-EA8CDB73-18E1-46EB-BB00-F5BDF4352CFEQ36239760-F6B1FA5E-CC7B-4255-9635-C6AF23E4ED15Q36250573-DE426F47-44C4-4E18-A507-F35F8598DC73Q36313467-4C99032B-E648-4A1E-8CB7-55C49CE48F3BQ36404749-198EC974-70A1-4BA2-9B1F-28A13E1B5B9FQ36844895-72D80B25-6480-4128-8E7C-B09B82F098F7Q36845205-1B0D35C2-7133-4662-953D-9432800CD54CQ37337879-8A532334-DA7A-4BAA-917A-E6CF1FE4200BQ37452401-75B43C8F-4AAF-47F8-9F58-10E3512934E7Q37949657-BE28CDAF-D728-4DBC-8430-AF184F5E922BQ38011299-B9DA3DBC-802C-4E72-8B9F-EE07E141C3ADQ38155197-678D18DE-17D3-4941-83D8-A80B7350026EQ38268922-6CE3E6AF-F22A-47F3-B00B-2C26831E7EFFQ38482586-EB888881-B7A9-428F-B98C-8DD947D86433Q39654344-129BE32E-0A7A-4682-B5F1-53F228B57131Q39757189-F788C298-4A48-454E-BC74-D238883F55CDQ41071866-5D45F895-480A-49A2-8306-91E02ADEB4CCQ41295048-A52A33ED-C527-4AD2-B123-0CC26DC06729Q41737626-B4528DAB-FA30-4C45-86CA-98E22E7FA5CDQ42732118-E2208904-F9B0-47C4-A6C7-8E0A5B12357FQ46689726-5138DCE2-0597-40A5-88F4-DBCB4CB7DB13Q49188733-2CADF754-F481-448B-A03B-D0DA0A43E0BC
P2860
Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Both Th1 and Th2 cytokines aff ...... ainst Cryptococcus neoformans.
@ast
Both Th1 and Th2 cytokines aff ...... ainst Cryptococcus neoformans.
@en
Both Th1 and Th2 cytokines aff ...... ainst Cryptococcus neoformans.
@nl
type
label
Both Th1 and Th2 cytokines aff ...... ainst Cryptococcus neoformans.
@ast
Both Th1 and Th2 cytokines aff ...... ainst Cryptococcus neoformans.
@en
Both Th1 and Th2 cytokines aff ...... ainst Cryptococcus neoformans.
@nl
prefLabel
Both Th1 and Th2 cytokines aff ...... ainst Cryptococcus neoformans.
@ast
Both Th1 and Th2 cytokines aff ...... ainst Cryptococcus neoformans.
@en
Both Th1 and Th2 cytokines aff ...... ainst Cryptococcus neoformans.
@nl
P2093
P2860
P1476
Both Th1 and Th2 cytokines aff ...... ainst Cryptococcus neoformans.
@en
P2093
A Casadevall
D O Beenhouwer
M D Scharff
M Feldmesser
P2860
P304
P356
10.1128/IAI.69.10.6445-6455.2001
P407
P577
2001-10-01T00:00:00Z